Clinical Research Directory
Browse clinical research sites, groups, and studies.
Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
Sponsor: Helwan University
Summary
The goal of this clinical trial is to compare the effectiveness of acetazolamide versus dapagliflozin as an add-on in treating acute decompensated heart failure (ADHF) in adult patients with clinical signs of volume overload requiring intravenous loop diuretics. It will also assess the safety of these drugs when added to standard care. The main questions it aims to answer are: * Does acetazolamide or dapagliflozin lead to a greater reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels? * Which drug results in better loop diuretic efficiency, as measured by weight loss per 40 mg of intravenous furosemide or equivalent? We will compare acetazolamide to dapagliflozin, both added to standard intravenous loop diuretic therapy, to see which is more effective in decongesting patients with ADHF. Participants will: * Take either acetazolamide or dapagliflozin orally every day for 3 days * Receive intravenous loop diuretics as part of standard care * Undergo regular assessments of heart failure symptoms, weight, and laboratory tests * Be followed up until hospital discharge and for 30 days after starting the study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-08-24
Completion Date
2025-09-01
Last Updated
2024-08-05
Healthy Volunteers
No
Conditions
Interventions
Acetazolamide
Patients will receive acetazolamide 500 mg once daily for 3 days as add on therapy to IV loop diuretics
Dapagliflozin 10mg
patient will receive oral dapagliflozin 10 mg once daily for 3 days as add on therapy to IV loop diuretics
Locations (1)
Critical Care Medicine Department - Cairo University Hospitals.
Cairo, Egypt